Results 161 to 170 of about 7,511 (210)

Therapeutic Efficacy of YH35324 on FcεRIα-Mediated Mast Cell/Basophil Activation. [PDF]

Allergy Asthma Immunol Res
Ryu MS, Yang EM, Ye YM, Jang JH, Kim J, Lee SY, Park HS.   +6 more
europepmc   +1 more source

Myasthenia gravis in 2025: five new things and four hopes for the future. [PDF]

J Neurol
Binks SNM, Morse IM, Ashraghi M, Vincent A, Waters P, Leite MI.   +5 more
europepmc   +1 more source

Engineering of anticancer human immunoglobulin A equipped with albumin for enhanced plasma half-life. [PDF]

PNAS Nexus
Mester S, Chan C, Lustig M, Foss S, Jansen JHM, Leangen Herigstad M, Evers M, Nilsen J, Reiding KR, A Damen JM, Burger R, Grevys A, Dalhus B, Valerius T, Sandlie I, Leusen JHW, Andersen JT.   +16 more
europepmc   +1 more source

Faculty Opinions recommendation of Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain.

, 2017
Chava Kimchi‐Sarfaty
openalex   +2 more sources

On the horizon: upcoming new agents for the management of ITP. [PDF]

Hematology Am Soc Hematol Educ Program
Lambert MP.
europepmc   +1 more source

Zilucoplan for Successful Early Weaning From Mechanical Ventilation and Avoiding Tracheostomy in an 85-Year-Old Woman Experiencing Myasthenic Crisis: A Case Report. [PDF]

Cureus
Ito S, Sugimoto T, Naito H, Aoki S, Nakamori M, Miyachi T, Yamazaki Y, Maruyama H.   +7 more
europepmc   +1 more source

Impact of FcRn antagonism on vaccine-induced protective immune responses against viral challenge in COVID-19 and influenza mouse vaccination models. [PDF]

Hum Vaccin Immunother
Warang P, Singh G, Moshir M, Binazon O, Laghlali G, Chang LA, Wouters H, Vanhoenacker P, Notebaert M, Elhemdaoui N, Augustynková K, Steeland S, Ulrichts P, Baumeister J, Schotsaert M.   +14 more
europepmc   +1 more source

Pemphigoid disease model systems for clinical translation. [PDF]

Front Immunol
Tigges M, Dräger S, Piccini I, Bieber K, Vorobyev A, Edelkamp J, Bertolini M, Ludwig RJ.   +7 more
europepmc   +1 more source

First line treatment with subcutaneous efgartigimod in impending myasthenic crisis: a case report. [PDF]

Ther Adv Neurol Disord
Kwiedor I, Menacher M, Ellßel M, Naumann M, Bayas A.   +4 more
europepmc   +1 more source

Translational population target binding model for the anti-FcRn fragment antibody efgartigimod. [PDF]

J Pharmacokinet Pharmacodyn
Hoefman S, van Steeg T, Ottevaere I, Baumeister J, Rossenu S.   +4 more
europepmc   +1 more source